| This week's sponsor is Biotech Primer. | |  | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Wednesday, May 2, 2018 Novartis' CAR-T cancer therapy Kymriah expanded its reach with a second FDA approval Tuesday night—an approval that puts it in direct competition with Gilead's Yescarta. If the rivalry in relapsed large B-cell lymphoma comes down to price, it will be a close race. |
|
|
| This week's sponsor is FierceBiotech Executive Breakfast at BIO 2018. | |  | |
Top Stories Of The Week Tuesday, May 1, 2018 Bristol-Myers Squibb has pulled two phase 3 clinical trials of the IDO1 inhibitor it acquired through an $800 million takeover of Flexus. The studies are the latest dominoes to fall following the failure of Incyte’s rival IDO drug to move the needle in a pivotal trial. Friday, April 27, 2018 It's not often that one misguided phone call—and a subsequent cover-up—costs a company hundreds of millions of dollars, but that's exactly what happened in a hepatitis C patent dispute between Merck & Co. and Gilead Sciences. Monday, April 30, 2018 AbbVie has terminated an early-stage trial of an antibody-drug conjugate (ADC) for solid tumors, one of the candidates acquired as part of its $9.8 billion takeover of Stemcentrx in 2016. Monday, April 30, 2018 GlaxoSmithKline's Shingrix carried high expectations, but it turns out that those ambitious projections weren't high enough. In the first quarter, the shingles vaccine generated £110 million, nearly triple analyst estimates of £40 million. And the revenue couldn't come at a better time for GSK. Wednesday, May 2, 2018 Daphne Koller has unveiled her next goal: improving drug R&D. The ex-Calico AI expert plans to enlist data and machines to address shortcomings in drug discovery and development—and she has persuaded a stellar investment syndicate to bankroll the work. Monday, April 30, 2018 Sermo’s drug ratings system by doctors for doctors is soaring. A little less than a year after its launch, the Yelp-like platform now has 655,000 ratings on more than 4,000 medications. More than half those drugs have at least 100 reviews—and 18 of them have more than 1,000. Monday, April 30, 2018 Bats can host several viruses without ever developing symptoms—even Marburg and Ebola, both of which can be deadly to people. So what’s the secret to the bats’ immunity, and could it point to new therapies to fight lethal viruses? Scientists from the U.S. Army are studying DNA from Egyptian fruit bats in the hopes of answering those questions. Tuesday, February 27, 2018 An Indian drugmaker has halted production of a couple of APIs for the U.S. after FDA inspectors found it was falsifying data at its manufacturing complex near Tamil Nadu, India. That was just the beginning of the problems. Wednesday, May 2, 2018 Charles River Laboratories is expanding its services into the early discovery setting, offering high-speed pharmacokinetics screening of compounds’ underlying biology to help companies identify small-molecule candidates. Resources Sponsored by: Veeva Systems Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation. Sponsored by: Veeva Systems Find out how to eliminate regulatory’s tracking spreadsheets for good. Sponsored by: Veeva Systems UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off. Sponsored by: Veeva Systems Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems. Sponsored by: Veeva Systems Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams. Sponsored by: Veeva Systems To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights. Sponsored by: Veeva Systems Explore a new model for events management, and learn how to deliver more value. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. | 
